CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service · Privacy FAQ

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Actinide›
Analysis
Actinide

Actinide

Actinide builds U.S. electromagnetic isotope separators and demonstrated research-scale HALEU enrichment.

Operating headquarters
Dallas, TX, US🇺🇸
Founded
2025
Loading
Overview
Analysis
Compare
Employees
News
Library

Contents

  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths
  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths

Product Overview

Actinide’s commercial flagship is enriched ytterbium-176 produced on Endurance, a modern electromagnetic isotope separator that sorts ions by mass. The company reports commercial shipments to Oklo Isotopes and more than 95% ytterbium-176 enrichment on that line.

In August 2026, Actinide reconfigured Endurance to enrich natural uranium and reported research-scale high-assay low-enriched uranium assayed at 15.38% uranium-235 by an ISO/IEC 17025 laboratory. Fortitude, its second-generation separator, is intended to expand domestic throughput for medicine, energy, and advanced materials.

Market Outlook

Demand for specialized isotopes spans radiopharmaceuticals, advanced nuclear fuel, semiconductors, and quantum systems, while U.S. civilian enrichment still relies heavily on foreign suppliers. The Department of Energy’s HALEU Availability Program states that HALEU is not currently available from domestic commercial suppliers at the scale advanced reactors need.

Actinide’s configurable electromagnetic approach aims at smaller, redeployable capacity that can serve high-value medical isotopes first and nuclear applications as licensing and scale allow. Research-scale HALEU at 15.38% uranium-235 does not itself create a commercial fuel supply; Fortitude throughput and licensing will decide how far the model extends.

Competitive Advantages

Actinide’s electromagnetic platform can switch between medical isotopes and uranium enrichment on the same machine, and it reports producing solid HALEU directly rather than uranium hexafluoride that still needs commercial deconversion.

That flexibility and form-factor claim matter while domestic centrifuge HALEU capacity remains limited and federal programs continue to fund conventional enrichment and deconversion buildout. Sustained Fortitude economics and commercial licensing will determine whether the advantage holds beyond research-scale demonstrations.